1 results for "Ki67".
Introduction: The choice of first-line treatment of metastatic pancreatic neuroendocrine tumors (mP-NET) is mainly based on prognostic factors. ENETS-2016 guidelines proposed treatments according to 3 groups: Group-1, patients in whom all lesions could be removed; Group-2, patients with Ki67<10%, low tumor burden, no symptoms, and stable disease, for whom a watch-and-wait strategy or somatostatin analogs are proposed; Group-3, symptomatic patients or with Ki67>10% or significant tumor burden or progressive disease, for whom a systemic chemotherapy is proposed
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Margaux Foulfoin